Chemomab Therapeutics Ltd DRC (CMMB) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $1.55
• Market Cap: $8.86M
• EPS: $-1.44
• 52-Week High: $7.04
• 52-Week Low: $1.35

Market Sentiment

Chemomab Therapeutics Ltd DRC currently has a Neutral sentiment score of 0.10.

About Chemomab Therapeutics Ltd DRC

Chemomab Therapeutics Ltd. is a clinical-stage biopharmaceutical firm headquartered in Tel Aviv, Israel, specializing in the development of innovative biological therapies for inflammatory and fibrotic diseases. The company’s lead candidate, CM-101, is a monoclonal antibody that targets critical pathways associated with fibrosis, demonstrating promise across multiple therapeutic indications. Chemomab is dedicated to harnessing its proprietary technology platform to deliver transformative trea...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Chemomab Therapeutics Ltd DRC and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does CMMB pay dividends?

Chemomab Therapeutics Ltd DRC (CMMB) does not currently pay a regular dividend.

What is CMMB's market cap?

Chemomab Therapeutics Ltd DRC (CMMB) has a market capitalization of $8.86M with a current stock price of $1.55.